We’re back again, this time with details on our models for de novo design and new, open sourced data on functionality and developability, going beyond binding. We show one design has 3x higher potency than trastuzumab! Paper: https://t.co/zW6vXSYK4Z Data: https://t.co/B6htidmFgE

We’re excited to announce our new strategic partnership with @precisionlifeAI. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. https://t.co/T4mJzoLovu

We @abscibio are excited to unveil IgDesign™ @NeurIPSConf and present our work at @workshopmlsb @AI4D3 @genbio_workshop! IgDesign is an antibody inverse folding model that we have experimentally validated in our lab. Read the paper here: https://t.co/H5xDtNt0NE #NeurIPS2023

We're excited to announce our new collaboration with @AstraZeneca! This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.

We are excited to announce our new collaboration with Almirall! We’ll be working together to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. https://t.co/4BWDiX2ybW

@abscibio @SeanRMcClain @zachjonasson Chief Innovation Officer Andreas Busch hopes to show his daughter that he can compete with #BFF with his own meme: Better Biologics Faster, or #BBF. 😜

@abscibio @SeanRMcClain @zachjonasson shared progress on scaling and integrating AI drug creation operations, including >15% efficiencies in integrating wet lab and AI teams this year

@abscibio @SeanRMcClain Sean announced that Absci is launching its own wholly-owned internal drug pipeline, focusing on #cytokine biology, that will complement its partnered discovery programs.

How @abscibio overcomes the fundamental data limitation in AI drug discovery - pooled approach to scaling antibodies in the wet lab. Millions or billions of candidates produced in a single experiment. That's training data for AI. -@SeanRMcClain

Participating in Absci R&D Day today. Now speaking: Sandi Peterson, Partner at Clayton Dubilier & Rice and Lead Independent Director for Microsoft’s Board of Directors.

What a strange and wonderful performance! Thank you @DrewEndy @specterm @ahmedbest. @SynBioBeta

You heard it here first: data is more important than models. Code to Cure panel moderated by @SeanRMcClain . @SynBioBeta @abscibio

E. coli is the unlikely hero of generative AI. Today it’s pharma, tomorrow it’s food, the next day it will be the stars! @SynBioBeta @abscibio

Creating drugs at the speed of Ai! ⁦@abscibio⁩ ⁦@SynBioBeta⁩ ⁦@SeanRMcClain⁩

Thrilled to be back at @synbiobeta this year! You can always count on @johncumbers for a big start to a big event!

I adore you, @PlazaAccount Aubrey Plaza, but why are you propagandizing against sustainable milk? 💔

Alex Phillipidis at @genbio does a great job of capturing what Absci does — and how it can go after the hardest part of the antibody with #generativeai and #synbio to create better #biologics for patients faster than ever.

Trillion. With a T. #synbio Green industries could be worth $10.3 trln to economy by 2050 - study | Reuters

Today, we announce a breakthrough in AI drug design: We’re the first to design AND validate new therapeutic antibodies with zero-shot #generativeAI. Read about it in our preprint: https://t.co/qI8j1YAird #JPM23

Good, I’m almost out of #bananas